Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence: Overview01:16

Bioequivalence: Overview

949
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
949
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

50
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
50
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

124
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
124
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

64
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
64
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

52
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
52
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

164
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
164

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Complex Distribution Phenomena and Plastic Binding of Test Chemicals in Cell Culture Experiments: Exemplification by Tebufenpyrad.

International journal of molecular sciences·2026
Same author

Virtual Bioequivalence Assessment of Long-Acting Injectable Suspensions Using PBPK Modeling: Part 2. Type I Error and Safe Space Analyses.

The AAPS journal·2026
Same author

Virtual Bioequivalence Assessment of Long-acting Injectable Suspensions Using PBPK Modeling: Part 1. Impact of particle Size on Formulation Variability.

The AAPS journal·2026
Same author

Assessing hepatic impairment with biomarker-informed physiologically based pharmacokinetic modeling: Strengths and limitations of the endogenous biomarker Coproporphyrin I.

Drug metabolism and disposition: the biological fate of chemicals·2025
Same author

From cellular perturbation to probabilistic risk assessments.

ALTEX·2025
Same author

Identifying human toxicodynamic variability: A systematic evidence map of the current knowledge.

Regulatory toxicology and pharmacology : RTP·2025

Related Experiment Video

Updated: Jun 17, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.7K

A Bayesian framework for virtual comparative trials and bioequivalence assessments.

Frederic Y Bois1, Céline Brochot1

  • 1Certara UK Limited, Certara Predictive Technologies Division, Sheffield, United Kingdom.

Frontiers in Pharmacology
|August 14, 2024
PubMed
Summary

A new Bayesian framework for virtual bioequivalence (VBE) assessments offers a more precise alternative to frequentist methods. This approach better controls consumer risk while minimizing producer risk, improving upon current VBE practices.

Keywords:
Bayesian inferencecomparative clinical trialspaliperidonesensitivity analysisvirtual bioequivalence assessment

More Related Videos

A Psychophysics Paradigm for the Collection and Analysis of Similarity Judgments
08:12

A Psychophysics Paradigm for the Collection and Analysis of Similarity Judgments

Published on: March 1, 2022

2.5K
A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research
09:35

A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research

Published on: August 16, 2017

17.8K

Related Experiment Videos

Last Updated: Jun 17, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.7K
A Psychophysics Paradigm for the Collection and Analysis of Similarity Judgments
08:12

A Psychophysics Paradigm for the Collection and Analysis of Similarity Judgments

Published on: March 1, 2022

2.5K
A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research
09:35

A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research

Published on: August 16, 2017

17.8K

Area of Science:

  • Pharmacometrics
  • Drug Development
  • Regulatory Science

Background:

  • Virtual bioequivalence (VBE) assessments utilize pharmacokinetic models and in vitro data to simulate large clinical trials.
  • Current frequentist VBE assessments, while controlling consumer risk, may impose unnecessary risks on producers due to simulation limitations.

Purpose of the Study:

  • To propose and demonstrate a fully Bayesian model-integrated VBE assessment framework.
  • To address limitations of frequentist VBE by minimizing producer risk and enhancing precision.

Main Methods:

  • A hypothetical case study involving a generic paliperidone palmitate long-acting injectable suspension was used.
  • The approach employed a validated population pharmacokinetic model and demonstrated Bayesian equivalents for bioequivalence testing, power, error analyses, and safe-space analyses.

Main Results:

  • The fully Bayesian workflow demonstrated superior precision compared to the frequentist workflow.
  • Decisions regarding bioequivalence and safe-space analyses differed significantly between the Bayesian and frequentist approaches, highlighting the greater accuracy of Bayesian methods.

Conclusions:

  • A Bayesian framework can effectively control consumer risk and minimize producer risk in VBE assessments.
  • This approach rewards data integration and the use of prior information, offering a more accurate and robust method for VBE.
  • Frequentist methods, though less precise, can serve as an initial step for parameter space exploration in safe-space analyses.